10438-96-7

Basic information

• Product Name: METHYLSULFAMOYL CHLORIDE
• Synonyms: METHYLSULFAMOYL CHLORIDE;Methylaminosulfonyl chloride;N-Methylaminosulfonyl chloride;N-Methylsulfamoyl chloride;N-methyl-Sulfamoyl chloride;(MethylsulfaMoyl)chloranuide
• CAS NO: 10438-96-7
• Molecular Formula: CH₄ClNO₂S
• Molecular Weight: 129.56596
• Mol File: 10438-96-7.mol

Chemical Properties

• Boiling Point: 188.9±23.0℃ (760 Torr)
• Flash Point: 68.0±22.6℃
• Appearance: /
• Density: 1.501±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.585mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.91±0.40(Predicted)
• CAS DataBase Reference: METHYLSULFAMOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYLSULFAMOYL CHLORIDE(10438-96-7)
• EPA Substance Registry System: METHYLSULFAMOYL CHLORIDE(10438-96-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 10438-96-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYLSULFAMOYL CHLORIDE is used as a synthetic intermediate for the development of substituted MEK inhibitors. These inhibitors play a crucial role in targeting specific enzymes involved in cellular signaling pathways, which can be beneficial for the treatment of various diseases, including cancer.
Additionally, METHYLSULFAMOYL CHLORIDE is used as a reagent in the preparation of therapeutic compounds. Its ability to form derivatives with potential medicinal properties makes it a valuable asset in the development of new drugs and treatments for a wide range of health conditions.

InChI:InChI=1/CH4ClNO2S/c1-3-6(2,4)5/h3H,1H3

Upstream product

• 4112-03-2 N-methylsulfamic acid 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 54838-83-4 Methylsulfamic acid 4-chlorophenyl ester 
• 70484-56-9 2-morpholin-4-yl-1-phenyl-ethenesulfonic acid methylamide 
• 26120-08-1 N-Methyl-N'-<3-nitro-phenyl>-sulfonyldiamid 
• 22504-72-9 N,N'-dimethylsulfamide 
• 26120-09-2 N-Benzyl-N'-methyl-sulfonyldiamid 
• 54838-82-3 Methyl-sulfamic acid 4-acetyl-phenyl ester 
• 26153-46-8 N-Methyl-amidosulfonsaeure-cyclohexylester 
• 97240-80-7 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose methylsulfamate 
• 96355-30-5 2-Oxo-2-phenyl-ethanesulfonic acid methylamide 
• 96355-28-1 2-Oxo-cyclohexanesulfonic acid methylamide 
• 102276-47-1 N-Methyl-N'-<(4-chlor-2-benzoyl)phenyl>-sulfamid 
• 102276-33-5 N-Methyl-1-phenyl-2-(phenylmethylen)-hydrazinsulfonamid 
• 179526-03-5 C₂₀H₂₇N₃O₅S 
• 203663-00-7 N-(1-benzylpiperidin-4-yl)-N'-methylsulfamide 

Relevant articles and documents

Regioselective C(sp3)-H alkylation of a fructopyranose derivative by 1,6-HAT

Regioselective C(sp3)-H alkylation of a fructopyranose derivative using electron-deficient alkenes as alkylation reagents was achieved. The reaction proceededvia1,6-hydrogen atom transfer under photoredox iridium catalysis. Several functional g

Intramolecular C?H Amination of N-Alkylsulfamides by tert-Butyl Hypoiodite or N-Iodosuccinimide

1,3-Diamines are an important class of compounds that are broadly found in natural products and are also widely used as building blocks in organic synthesis. Although the intramolecular C?H amination of N-alkylsulfamide derivatives is a reliable method for the construction of 1,3-diamine structures, the majority of these methods involve the use of a transition-metal catalyst. We herein report on a new transition-metal-free method using tert-butyl hypoiodite (t-BuOI) or N-iodosuccinimide (NIS), enabling secondary non-benzylic and tertiary C?H amination reactions to proceed. The cyclic sulfamide products can be easily transformed into 1,3-diamines. Mechanistic investigations revealed that amination reactions using t-BuOI or NIS each proceed via different pathways.

Catalytic Sulfamoylation of Alcohols with Activated Aryl Sulfamates

We report a new catalytic method for alcohol sulfamoylation that deploys electron-deficient aryl sulfamates as activated group transfer reagents. The reaction utilizes the simple organic base N-methylimidazole, proceeds under mild conditions, and provides

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from -N= etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from -CH 2 - etc., and R 2 is selected from C 1-6 alkyl etc.

BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER

Provided is a novel compound having bromodomain and extra terminal domain (BET) protein inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of precancerous transformation or cancer.

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 6-aryl substituent

Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d] pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase α (PI3K-α), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC50 against mTOR and greater than 1000-fold selectivity over PI3K-α. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC50501 nM). 2009 American Chemical Society.

THROMBIN INHIBITORS

The present invention relates to a compound having formula I:and pharmaceutically acceptable salts thereof. The compounds of formula I and pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants.

Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with sulfonylureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. 1wherein: Z is 2Q is selected from the group consisting of: 3—W— is 4—represents a carbon-carbon bond or does not exist; and A is NR13R14.

Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents

The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and methods of using the same as antiproliferative agents or to prevent apoptosis.